Adjuvants

Discover research-grade vaccine adjuvants designed for reproducibility and performance.

At Avanti Research™, we offer a focused line of research adjuvants designed to support vaccine development and preclinical drug and immunology research. Our synthetic vaccine immunostimulators, like PHAD™ and TDB, are trusted by university scientists, biotech startups, and pharmaceutical companies around the world.

If you're exploring new vaccines or evaluating immune responses in preclinical settings, our highly pure synthetic vaccine adjuvants, designed for reproducibility and performance, would be a first-rate addition to your work.

Our curated adjuvant portfolio helps researchers improve how vaccines and treatments trigger immune responses in the body. Whether you're studying infectious diseases, cancer, or autoimmune conditions, our high-quality compounds give you the tools to push your research further with confidence.

Beyond the research stage, Avanti Research™ partners with Croda Pharma to provide a selection of GMP-grade lipids to support your clinical development needs.

What are adjuvants, and why are they critical in vaccine development?

Adjuvants are compounds and formulations that help with the immune system's response to a vaccine antigen. While the antigen introduces the immune system to the target pathogen, the adjuvant heightens the signal, which helps to produce a more powerful and lasting immune response.

Various mechanisms can trigger the immune response. One well-known mechanism is based on immune receptors like toll-like receptors (TLRs), which improve antigen presentation and attract immune cells to the injection site. This results in more robust activation of T and B lymphocytes, which are essential to the evolution of human immunity. According to Nature Reviews Immunology, this is especially important for vaccines that use small pieces of a virus or bacteria instead of a whole organism.

The Mechanisms of Adjuvant Action study from the National Library of Medicine further supports this, emphasizing how immunological adjuvants can shape the kind of immune response the body produces, like whether it leans more toward antibody production or cellular immunity.

In short, many vaccines would fail to generate the protection required for effective disease prevention without vaccine adjuvants.

Choose the right adjuvant for your research.

Different research goals call for different adjuvants. Selecting vaccine adjuvants and immunostimulators that are right for your study means understanding both the immune pathway they activate and the type of formulation they support.

Each compound is manufactured with the highest purity standards for consistent performance across multiple platforms. Whether you're optimizing a tuberculosis vaccine or improving mucosal immunity, Avanti Research™ adjuvants offer flexibility and targeted immune activation.

We have also formulated adjuvant systems like CAF (cationic adjuvant formulation) in our portfolio, available through our partnership with Croda Pharma:

• CAF01 is a two-component liposomal suspension composed of dimethyldioctadecyl ammonium (DDA) and C-type lectin receptor agonist trehalose dibehenate (TDB).
• CAF09b is a second-generation, three-component liposome-based vaccine adjuvant based on cationic surfactant dimethyldioctadecyl ammonium (DDA) combined with C-type lectin receptor agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I: C (polyinosinic-polycytidylic acid).

What are the formulation benefits of CAF?

CAF adjuvants are more than just potent immunostimulators; they’re built for real-world applications. Providing a range of benefits, these cationic liposomal formulations benefits are ideal for both preclinical and clinical use.

• Stable, well-characterized liposomes: CAF adjuvants are designed to be freeze-dried, have undergone safety evaluation in toxicology and human trials, and are manufactured using an up-scalable GMP process.
• Simple formulation process: Antigens can be easily mixed or reconstituted with CAF adjuvants.
• Strong immunogenicity support: Antigen absorption onto CAF is especially beneficial when strong T-cell responses are required, offering researchers flexibility depending on their immune response goals.

By combining the highest safety standards, scalable production, and flexible formulation design, CAF adjuvants give you a solid foundation for advancing your vaccine research from the lab to the clinic.

Need help selecting the right compound for your next formulation? Contact our Adjuvant Division to discuss your goals and get expert insights.

Avanti Research adjuvants are trusted by scientists worldwide.

Our adjuvants are trusted by researchers all over the world and frequently cited in peer-reviewed publications like the ones below:

• Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms – PMC.
• Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability – Springer Nature
• Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity – Taylor & Francis Online.
• Liposome-based cationic adjuvant formulations (CAF): Past, present, and future – Taylor & Francis Online.
• Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection – PMC.
• Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection – eBioMedicine.